[go: up one dir, main page]

WO2012016133A3 - Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers - Google Patents

Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers Download PDF

Info

Publication number
WO2012016133A3
WO2012016133A3 PCT/US2011/045876 US2011045876W WO2012016133A3 WO 2012016133 A3 WO2012016133 A3 WO 2012016133A3 US 2011045876 W US2011045876 W US 2011045876W WO 2012016133 A3 WO2012016133 A3 WO 2012016133A3
Authority
WO
WIPO (PCT)
Prior art keywords
glioblastoma
treatment
kinase inhibitors
ros1 kinase
deficient cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/045876
Other languages
French (fr)
Other versions
WO2012016133A2 (en
Inventor
Dorre Grueneberg
Ed Harlow
Jun XIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2012016133A2 publication Critical patent/WO2012016133A2/en
Publication of WO2012016133A3 publication Critical patent/WO2012016133A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods and compositions for treating tumors, including glioblastomas, using inhibitors of ROS1. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor ROS1 kinases that are required for growth of tumor cells but not normal cells.
PCT/US2011/045876 2010-07-29 2011-07-29 Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers Ceased WO2012016133A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40057810P 2010-07-29 2010-07-29
US61/400,578 2010-07-29

Publications (2)

Publication Number Publication Date
WO2012016133A2 WO2012016133A2 (en) 2012-02-02
WO2012016133A3 true WO2012016133A3 (en) 2012-04-26

Family

ID=45530737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045876 Ceased WO2012016133A2 (en) 2010-07-29 2011-07-29 Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers

Country Status (1)

Country Link
WO (1) WO2012016133A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9061008B2 (en) 2011-12-21 2015-06-23 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9884818B2 (en) 2013-05-17 2018-02-06 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US12503439B2 (en) 2023-04-21 2025-12-23 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (en) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Method for producing cycloalkylcarboxamido-indole compounds
EP2776405A1 (en) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
WO2014141129A2 (en) 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CA2935719C (en) 2013-07-25 2021-11-02 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
ES2968371T3 (en) 2013-10-10 2024-05-09 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
CA2920791C (en) 2013-10-14 2021-11-16 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
RS59911B1 (en) 2013-10-14 2020-03-31 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
JP6495929B2 (en) 2014-02-06 2019-04-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Sulfamoyl pyrrolamide derivatives and their use as medicaments for the treatment of hepatitis B
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PT3105218T (en) 2014-02-13 2019-12-05 Incyte Corp Cyclopropylamines as lsd1 inhibitors
DK3105226T3 (en) 2014-02-13 2019-10-14 Incyte Corp CYCLOPROPYLAMINES AS LSD1 INHIBITORS
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
PT3131582T (en) 2014-04-15 2018-10-08 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
TWI687419B (en) 2014-07-10 2020-03-11 美商英塞特公司 Imidazopyridines and imidazopyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US11299496B2 (en) 2014-07-23 2022-04-12 Northeastern University Ligands for alpha-7 nicotinic acetylcholine receptors and methods of treating neurological and inflammatory conditions
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX382097B (en) 2015-05-05 2025-03-13 Pfizer 2-thiopyrimidinones
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR102710120B1 (en) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Salt of LSD1 inhibitor
TW201718496A (en) 2015-09-29 2017-06-01 諾維拉治療公司 Crystalline forms of a hepatitis B antiviral agent
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (en) 2015-11-19 2023-04-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018071048A2 (en) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinations and methods comprising a capsid assembly inhibitor
PE20190377A1 (en) 2016-04-22 2019-03-08 Incyte Corp FORMULATIONS OF AN LSD INHIBITOR 1
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (en) 2016-05-26 2018-03-16 美商英塞特公司 Heterocyclic compounds as immunomodulators
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
MD3472167T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47123A (en) 2016-12-22 2021-03-17 Incyte Corp BENZOOXAZOLE DERIVATIVES AS MMUNOMODULATORS
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
PE20200005A1 (en) 2016-12-22 2020-01-06 Incyte Corp DERIVATIVES OF TETRAHYDRO IMIDAZO [4,5-C] PYRIDINE AS INDUCTORS OF INTERNALIZATION PD-L1
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
AU2018205275B2 (en) 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
JP6997197B2 (en) 2017-01-23 2022-01-17 カデント セラピューティクス，インコーポレーテッド Potassium channel modulator
EP3615529B1 (en) 2017-04-26 2024-06-05 Basilea Pharmaceutica International AG, Allschwil Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
EP3615532A4 (en) * 2017-04-28 2020-11-18 Dana Farber Cancer Institute, Inc. TRIM33 INHIBITORS AND METHOD OF USE
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
MA52019A (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co CAPSIDE ASSEMBLY MODULATOR DOSAGE SCHEDULE
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
PL4212529T3 (en) 2018-03-30 2025-07-07 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
HRP20230306T1 (en) 2018-05-11 2023-05-12 Incyte Corporation TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
AU2019344897B2 (en) 2018-09-18 2024-01-18 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
MX2021004647A (en) 2018-10-22 2021-08-16 Novartis Ag Crystalline forms of potassium channel modulators.
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
ES2949999T3 (en) 2018-12-06 2023-10-04 Constellation Pharmaceuticals Inc TREX1 Modulators
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
EA202191890A1 (en) 2019-01-18 2022-02-03 Астразенека Аб PCSK9 INHIBITORS AND METHODS FOR THEIR USE
KR20220007845A (en) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. Compounds and uses thereof
CA3127152A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
EP3924348A4 (en) * 2019-03-21 2023-03-22 University of Virginia Patent Foundation SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND ASSOCIATED USES
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
UY38687A (en) 2019-05-17 2023-05-15 Novartis Ag NLRP3 INFLAMMASOME INHIBITORS, COMPOSITIONS, COMBINATIONS THEREOF AND METHODS OF USE
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
PL4031547T3 (en) 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CR20220237A (en) 2019-11-11 2022-08-05 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CN111205303B (en) * 2020-03-03 2021-04-27 四川大学 Thieno[2,3-d]pyrimidinyl hydroxamic acid derivatives and uses thereof
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP2023527379A (en) * 2020-05-27 2023-06-28 コンステレーション・ファーマシューティカルズ・インコーポレイテッド Substituted benzamides as modulators of TREX1
AR124001A1 (en) 2020-11-06 2023-02-01 Incyte Corp PROCESS FOR MANUFACTURING A PD-1 / PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
DK4347031T3 (en) 2021-06-04 2025-12-01 Vertex Pharma N-(HYDROXYALKYL-(HETERO)ARYL)-TETRAHYDROFURAN-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
US20240408072A1 (en) * 2021-10-27 2024-12-12 Esgelbio Inc. Composition for preventing or treating graves' disease comprising compound containing an imidazopyridine structure as active ingredient
TW202325289A (en) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4486719A1 (en) 2022-03-02 2025-01-08 Horizon Therapeutics Ireland DAC Process of making a crystalline edg-2 receptor antagonist
UY40374A (en) 2022-08-03 2024-02-15 Novartis Ag NLRP3 INFLAMASOME INHIBITORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BYUNG SUN PARK ET AL.: "Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 16, 2009, pages 4720 - 4723, XP026419064 *
HYUN JUNG JUN ET AL.: "Epigenetic Regulation of c-ROS receptor tyrosine kinase expression in Malignant gliomas", CANCER RESEARCH, vol. 69, no. 6, 2009, pages 2180 - 2184 *
IBRABIM MUSTAFA EL-DEEB ET AL.: "ROS Receptor Tyrosine Kinase: A New Potential target for Anticancer Drugs", MEDICINAL RESEARCH REVIEWS, vol. 31, no. 5, 2011, pages 794 - 818 *
IBRAHIM M. EL-DEEB ET AL.: "Design, synthesis, screening, and molecular modeling study of a new series or ROS1 receptor tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 19, 2009, pages 5622 - 5626 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061008B2 (en) 2011-12-21 2015-06-23 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9066932B2 (en) 2011-12-21 2015-06-30 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9205079B2 (en) 2013-03-12 2015-12-08 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9579313B2 (en) 2013-03-12 2017-02-28 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9884818B2 (en) 2013-05-17 2018-02-06 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9505722B2 (en) 2014-01-16 2016-11-29 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US12503439B2 (en) 2023-04-21 2025-12-23 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Also Published As

Publication number Publication date
WO2012016133A2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2010141738A3 (en) Compositions and method for inhibiting tumor growth
MX2015007205A (en) Histone demethylase inhibitors.
MX360404B (en) Compounds for inhibiting cell proliferation in egfr-driven cancers.
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
HK1210611A1 (en) Histone demethylase inhibitors
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
WO2012015914A3 (en) Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
CL2012003680A1 (en) Compounds derived from (1,8) 2,4 diaryl naphthyridines substituted kinase inhibitors; its procedure for obtaining; pharmaceutical composition; and its use for the treatment and / or prevention of cancer, tumor, malignant tumors, among others; Pharmaceutical kit
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
WO2012170827A3 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
MX2011012369A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors.
WO2011159685A3 (en) Inhibition of wdr5 interaction with its binding partners and therapeutic methods
MX357502B (en) Pyrrolotriazinone derivatives.
WO2013093508A3 (en) Wnt pathway inhibitors
WO2010104598A3 (en) Kinase protein binding inhibitors
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
WO2012135641A3 (en) Aurora kinase inhibitors and methods of making and using thereof
WO2011146568A8 (en) Predicting response to a her inhibitor
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813240

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813240

Country of ref document: EP

Kind code of ref document: A2